The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
Leerink notes that the FDA today declared an end to the tirzepatide shortage, which “seemingly begins the process of bringing the compounded ...
The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...
Credit: Eli Lilly. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). Compounding pharmacies must now cease producing the lucrative ...